| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
CASI Pharmaceuticals Inc (NASDAQ: CASI)
CASI Technical Analysis
5
| As on 12th Jun 2025 CASI STOCK Price closed @ 1.79 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 5.17 & Strong Sell for SHORT-TERM with Stoploss of 6.16 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CASISTOCK Price
| Open | 1.81 | Change | Price | % |
| High | 1.81 | 1 Day | -0.04 | -2.19 |
| Low | 1.79 | 1 Week | -0.07 | -3.76 |
| Close | 1.79 | 1 Month | -0.21 | -10.50 |
| Volume | 2587 | 1 Year | -4.34 | -70.80 |
| 52 Week High 7.85 | 52 Week Low 1.71 | ||||
NASDAQ USA Most Active Stocks
| GNLN | 0.02 | 100.00% |
| HCTI | 0.03 | 200.00% |
| AMRS | 0.14 | 100.00% |
| NCNA | 0.15 | -6.25% |
| NVDA | 145.00 | 1.52% |
| LMDX | 0.02 | 0.00% |
| TSLA | 319.11 | -2.24% |
| AKTS | 0.04 | 0.00% |
| PLUG | 1.30 | -5.80% |
| RSLS | 3.11 | 35.81% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CASI Daily Charts |
CASI Intraday Charts |
Whats New @ Bazaartrend |
CASI Free Analysis |
|
|
CASI Important Levels Intraday
| RESISTANCE | 1.83 |
| RESISTANCE | 1.82 |
| RESISTANCE | 1.81 |
| RESISTANCE | 1.80 |
| SUPPORT | 1.78 |
| SUPPORT | 1.77 |
| SUPPORT | 1.76 |
| SUPPORT | 1.75 |
CASI Forecast June 2025
| 4th UP Forecast | 8.69 |
| 3rd UP Forecast | 6.48 |
| 2nd UP Forecast | 5.11 |
| 1st UP Forecast | 3.74 |
| 1st DOWN Forecast | -0.16 |
| 2nd DOWN Forecast | -1.53 |
| 3rd DOWN Forecast | -2.9 |
| 4th DOWN Forecast | -5.11 |
CASI Weekly Forecast
| 4th UP Forecast | 4.68 |
| 3rd UP Forecast | 3.75 |
| 2nd UP Forecast | 3.18 |
| 1st UP Forecast | 2.61 |
| 1st DOWN Forecast | 0.97 |
| 2nd DOWN Forecast | 0.40 |
| 3rd DOWN Forecast | -0.17 |
| 4th DOWN Forecast | -1.10 |
CASI Forecast2025
| 4th UP Forecast | 14.28 |
| 3rd UP Forecast | 10.27 |
| 2nd UP Forecast | 7.8 |
| 1st UP Forecast | 5.32 |
| 1st DOWN Forecast | -1.74 |
| 2nd DOWN Forecast | -4.22 |
| 3rd DOWN Forecast | -6.69 |
| 4th DOWN Forecast | -10.7 |
CASI Pharmaceuticals Inc ( NASDAQ USA Symbol : CASI )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CASI Business Profile
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland. Address: 9620 Medical Center Drive, Rockville, MD, United States, 20850
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service